Oocyte Retrieval and Virtual Reality (REVPO) (REVPO)

June 12, 2023 updated by: University Hospital, Clermont-Ferrand

Study of Analgesic Effect of Virtual Reality During Oocyte Retrieval in In Vitro Fecondation Protocols: Controlled Randomized Trial

The aim of the study is to ass wether or not the use of virtual reality during oocyte retrieval provides a better pain relief for patients, compared to a standard analgesic procedure.

Study Overview

Detailed Description

Patients will be included during the consultation with the gynaecologist, whom will explain the protocol to the patient and give her the consent to sign.

The patient will be then randomized by a computer (using the software REDCAP) into either the experimental group or the standard group.

In the experimental group, a virtual reality device will be installed on the patient as soon as she arrives in the operating room, and the intervention will start after 3-5 minutes.

In both group, the patient will benefit of a local anesthesia in the vagina, and if they want it of an oral analgesic before the intervention.

Just at the end of the intervention, the pain will be evaluated orally by the nurse, using a Numeric Rating Scale. This consist of the Primary Outcome.

After the intervention, the gynaecologist will fill a form assessing his satisfaction concerning the use of virtual reality during the intervention (efficacy, security...) One hour after the intervention, the patient will fill a form about her self-estimation of the post-procedural pain and her satisfaction concerning the use of virtual reality.

The number of oocytes collected and the number of oocytes expected on the ultrasound monitoring will be gathered and a ratio will be calculated, in order to estimate the efficacy of the retrieval.

Five days after the intervention, the patient will have to fill a form evaluating her consumption of painkillers during the 48hours following the intervention.

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Clermont-Ferrand, France, 63000
        • Recruiting
        • CHU de Clermont-Ferrand
        • Sub-Investigator:
          • Florence Brugnon
        • Principal Investigator:
          • Camille Valdeyron
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 43 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Aged between 18 and 43 years
  • First attempt of oocyte retrieval under local anesthesia in the context of a protocol for Medically Assisted Procreation

Exclusion Criteria:

  • Former attempt of oocyte retrieval
  • Poor oocyte stock : > 40 years AND low markers (AMH < 0.5-1.1 ng/ml OR AFC < 5-7)
  • Unsteady epilepsia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Virtual Reality Group
in this group, patients will use virtual reality during the oocyte retrieval plus the standard anesthesic procedure (local anesthesia)
A virtual reality device will be install on the patient 3-5 minutes before the beginning of the oocyte retrieval. The device will be wearing by the patient during the entire intervention and 2 minutes after the end of the ponction.
standard anesthesic procedure
Sham Comparator: Standard Group
in this group, patients will receive the standard anesthesic procedure during the oocyte retrieval wich is local anesthesia
standard anesthesic procedure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain during oocyte retrieval, assessed by NRS
Time Frame: day 0 (During the intervention for oocyte retrieval)
Oral evaluation of pain during the intervention for oocyte retrieval, evaluated by a Numeric Rating Scale (NRS) : from 0 (meaning no pain at all) to 10 (meaning worse pain possible).
day 0 (During the intervention for oocyte retrieval)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain after oocyte retrieval, assessed by NRS
Time Frame: hour 1 (In the hour following the oocyte retrival)
Written evaluation of pain after the intervention for oocyte retrieval, evaluated by a Numeric Rating Scale (NRS) : from 0 (meaning no pain at all) to 10 (meaning worse pain possible).
hour 1 (In the hour following the oocyte retrival)
Painkillers consumption during the 48 hours following the oocyte retrieval.
Time Frame: Day 5
Written auto-evaluation (questionnaire) of the amount and type of painkillers taken by the patient during the 48hours following the intervention
Day 5
Patient satisfaction concerning the use of virtual reality during the oocyte retrieval
Time Frame: hour 1 (In the hour following the oocyte retrival)
Written evaluation of the patient global satisfaction concerning the virtual reality during the oocyte retrieval. (2 questions : "Concerning the use of virtual reality during the oocyte retrieval, are you : very satisfied, little satisfied, not satisfied, not at all satisfied"; "if you had to re-take an oocyte retrieval, would you : do it again with virtual reality, do it again without virtual reality, do it under general anesthesia")
hour 1 (In the hour following the oocyte retrival)
Gynaecologist satisfaction concerning the use of virtual reality during the oocyte retrieval
Time Frame: hour 1 (In the hour following the oocyte retrival)
Written evaluation of the gynaecologist satisfaction concerning the use of virtual reality during the oocyte retrieval (4 questions : "Concerning the security during the oocyte retrieval, are you very satisfied, little satisfied, not satisfied, not at all satisfied", "Concerning the easiness of the oocyte retrieval, are you very satisfied, little satisfied, not satisfied, not at all satisfied", "During the oocyte retrieval, the patient seemed : very relaxed, relaxed, not relaxed, not at relaxed"; "as a whole, if this patient should re-take an oocyte retrieval, ould you recommend the use of virtual reality? Yes/No, can you tell us why in a few words")
hour 1 (In the hour following the oocyte retrival)
Efficacy of the use of virtual reality during oocyte retrieval
Time Frame: hour 1 (In the hour following the oocyte retrival)
Ratio between the number of oocytes collected during the retrieval compared to the number of oocytes expected on the ultrasound monitoring
hour 1 (In the hour following the oocyte retrival)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Camille Valdeyron, University Hospital, Clermont-Ferrand

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 9, 2021

Primary Completion (Estimated)

December 1, 2024

Study Completion (Estimated)

December 1, 2024

Study Registration Dates

First Submitted

May 25, 2021

First Submitted That Met QC Criteria

June 15, 2021

First Posted (Actual)

June 23, 2021

Study Record Updates

Last Update Posted (Actual)

June 13, 2023

Last Update Submitted That Met QC Criteria

June 12, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • AOI 2020 VALDEYRON
  • 2020-A03233-36 (Other Identifier: ANSM)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on Hypnotic relaxation induced by virtual reality (device)

Subscribe